Ad is loading...
EDIT
Price
$2.14
Change
+$0.23 (+12.04%)
Updated
Dec 6 closing price
79 days until earnings call
NTLA
Price
$14.71
Change
+$1.06 (+7.77%)
Updated
Dec 6, 04:59 PM (EDT)
73 days until earnings call
Ad is loading...

EDIT vs NTLA

Header iconEDIT vs NTLA Comparison
Open Charts EDIT vs NTLABanner chart's image
Editas Medicine
Price$2.14
Change+$0.23 (+12.04%)
Volume$2.79M
CapitalizationN/A
Intellia Therapeutics
Price$14.71
Change+$1.06 (+7.77%)
Volume$34.59K
CapitalizationN/A
EDIT vs NTLA Comparison Chart
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
EDIT vs. NTLA commentary
Dec 09, 2024

Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) are genome research companies in Cambridge, MA founded just after the advent of CRISPR technology in 2012. They develop innovative treatments with gene editing, with a high concentration of Ph.D. and M.D. employees working in multiple collaborations with large pharmaceutical companies that provide additional capital and resources. Fiercely in competition with one another, they seek niches to call their own. NTLA has focused slightly more on blood-related disorders while EDIT has primarily taken aim at cancer and neurological disorders. Both have only reported negative earnings while they strive to bring viable treatments to market. Genome research has been a contentious topic for some time, so political climate is a big variable, and news events cause wild swings in the prices of both. NTLA’s market cap grew significantly in 2021, but it remains to be seen if this will give it a lasting advantage over EDIT.

COMPARISON
Comparison
Dec 09, 2024
Stock price -- (EDIT: $2.14 vs. NTLA: $14.72)
Brand notoriety: EDIT and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 124% vs. NTLA: 104%
Market capitalization -- EDIT: $157.67M vs. NTLA: $1.39B
EDIT [@Biotechnology] is valued at $157.67M. NTLA’s [@Biotechnology] market capitalization is $1.39B. The market cap for tickers in the [@Biotechnology] industry ranges from $489.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.71B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both EDIT and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 4 bearish.
  • NTLA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -4.46% price change this week, while NTLA (@Biotechnology) price change was -5.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -2.68%, and the average quarterly price growth was +10.76%.

Reported Earning Dates

EDIT is expected to report earnings on Feb 26, 2025.

NTLA is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.39B) has a higher market cap than EDIT($158M). NTLA YTD gains are higher at: -51.722 vs. EDIT (-78.875). EDIT has higher annual earnings (EBITDA): -222.63M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. EDIT (265M). EDIT has less debt than NTLA: EDIT (38.5M) vs NTLA (102M). EDIT has higher revenues than NTLA: EDIT (61.8M) vs NTLA (43.1M).
EDITNTLAEDIT / NTLA
Capitalization158M1.39B11%
EBITDA-222.63M-527.52M42%
Gain YTD-78.875-51.722152%
P/E RatioN/AN/A-
Revenue61.8M43.1M143%
Total Cash265M658M40%
Total Debt38.5M102M38%
FUNDAMENTALS RATINGS
EDIT vs NTLA: Fundamental Ratings
EDIT
NTLA
OUTLOOK RATING
1..100
5016
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
32
Undervalued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
9586
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (18) in the Biotechnology industry is in the same range as NTLA (32). This means that EDIT’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as EDIT (100). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as EDIT (98). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

NTLA's Price Growth Rating (86) in the Biotechnology industry is in the same range as EDIT (95). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that NTLA’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITNTLA
RSI
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
84%
Momentum
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
N/A
Bullish Trend 8 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
83%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIIOX26.450.12
+0.46%
Marsico International Opportunities Inst
MITEX13.720.01
+0.07%
Matthews Asia Innovators Institutional
UGTAX28.670.02
+0.07%
Victory Growth and Tax Strategy A
HISVX43.43-0.18
-0.41%
Harbor Small Cap Value Investor
MCBVX33.44-0.17
-0.51%
MFS Mid Cap Value B

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+7.84%
VCYT - NTLA
69%
Closely correlated
+3.01%
EDIT - NTLA
68%
Closely correlated
+12.04%
BEAM - NTLA
66%
Closely correlated
+5.49%
CRSP - NTLA
61%
Loosely correlated
+5.70%
PRME - NTLA
59%
Loosely correlated
+10.10%
More